Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the proposed interim limit.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Golden State Medical Supply Inc. |
| NDC | 60429-165-30 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottles, NDC 60429-165-30; b) 90 capsules bottles, NDC 60429-165-90, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Packaged by GSMS, Incorporated, Camarillo, CA 93012. |
| Recalling firm | Golden State Medical Supply Inc. |
| Distribution | Nationwide in the U.S. |
| Quantity | 21,655 (30 count bottle), 34,149 (90 count bottle) |
| Recall initiated | 2024-05-13 |
| Report date | 2024-07-03 |
| Recall completed | 2025-03-20 |
| Recall number | D-0568-2024 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Camarillo CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗